Drug establishment licences and COVID-19

All Canadian drug establishments must have a drug establishment licence to fabricate, package/label, distribute, import, wholesale or test a drug as required under Part C, Division 1A of the Food and Drug Regulations.

Données et ressources

Info additionnelle

Champ Valeur
Source
Version
Producteur
Courriel de l'auteur
Mainteneur
Courriel du mainteneur
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Les licences d’établissement de produits pharmaceutiques et la COVID-19
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Langue
Contact Person
Contact Email
Dictionnaire de données
Open Canada Date Published 2020-08-08 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Pandémie de COVID-19", "licences d’établissement de produits pharmaceutiques", "Partie C", "Division 1A du Règlement sur les aliments et drogues"], "en": ["COVID-19 pandemic", "Drug establishment licences", "Part C", "Division 1A of the Food and Drug Regulations."]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source